 | Up a level |
Ghisoni, E; Wicky, A; Bouchaab, H; Imbimbo, M; Delyon, J; Gautron Moura, B; Gérard, C L; Latifyan, S; Özdemir, B.C.; Caikovski, M; Pradervand, S; Tavazzi, E; Gatta, R; Marandino, L; Valabrega, G; Aglietta, M; Obeid, M; Homicsko, K; Mederos Alfonso, N N; Zimmermann, S; ... (2021). Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy. European journal of cancer, 149, pp. 153-164. Elsevier 10.1016/j.ejca.2021.03.010
von Moos, R; Seifert, B; Simcock, M; Goldinger, S M; Gillessen, S; Ochsenbein, A; Michielin, O; Cathomas, R; Schläppi, M; Moch, H; Schraml, P H; Mjhic-Probst, D; Mamot, C; Schönewolf, N; Dummer, R; Swiss Group for Clinical Cancer Research, (SAKK) (2012). First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). Annals of oncology, 23(2), pp. 531-6. Oxford: Oxford University Press 10.1093/annonc/mdr126
